Palisade Bio, Inc. (PALI) Research

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

Market snapshot

Symbol
PALI
Price
$1.87
Day change
+6.25%
Market cap
$324.6M
P/E ratio
-16.23x
52-week range
0.53-2.86
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$1.50

Peer companies

  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Athira Pharma, Inc. (ATHA)
  • BriaCell Therapeutics Corp. (BCTX)
  • Curis, Inc. (CRIS)
  • Citius Pharmaceuticals, Inc. (CTXR)
  • Daré Bioscience, Inc. (DARE)
  • Entero Therapeutics, Inc. (ENTO)
  • Hoth Therapeutics, Inc. (HOTH)

Recent insider activity

  • Baltera Robert Jr. — A-Award (336904 shares) on 2026-06-10
  • Baltera Robert Jr. — trade (0 shares) on 2026-06-10
  • Wei Binxian — M-Exempt (20200 shares) on 2026-06-10
  • Wei Binxian — A-Award (592300 shares) on 2026-06-10
  • Wei Binxian — M-Exempt (20200 shares) on 2026-06-10

Open Palisade Bio, Inc. (PALI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.